Abstract The P2X 7 receptor is an important regulator of epithelial cell growth. The aim of the present study was to better understand the biological significance of P2X 7 receptor expression in normal and cancer human epithelial tissues. P2X 7 receptor and messenger RNA (mRNA) levels were determined in human tissues containing epithelial dysplastic, pre-or early cancerous, and cancer cells, and the levels were compared to those in the corresponding normal epithelial cells within the same tissue of the same case. P2X 7 receptor levels were determined by quantification of immunoreactivity specific to the functional (full-length) P2X 7 receptor, and P2X 7 mRNA levels were determined by real-time polymerase chain reaction. P2X 7 receptor levels in cancer cells were similar (colon adenocarcinoma) or greater (thyroid papillary carcinoma) than those in the corresponding normal cells. In contrast, in cancer cells of the ectocervix (squamous), endocervix and endometrium (adenocarcinoma), urinary bladder (transitional cell carcinoma), and breast (ductal and lobular adenocarcinomas), P2X 7 receptor levels were lower by about twofold than those in the corresponding normal epithelial cells. Similarly, P2X 7 mRNA levels were lower in uterine, bladder, and breast cancer epithelial tissues by about fourfold than those in the corresponding normal tissues. In addition, P2X 7 receptor levels were decreased already in dysplastic ectocervical cells and pre-or early cancerous endometrial and bladder cells. The data suggest that in epithelia originating from the ectoderm, the uro-genital sinus, and the distal paramesonephric duct, decreased expression of the P2X 7 receptor precedes or coincides with neoplastic changes in those tissues.
Introduction
The main cellular mechanism that controls growth of epithelial cells is apoptosis. Apoptosis is a regulated homeostatic process orchestrated by the host's genome of selective cell deletion without stimulating inflammatory response [1] [2] [3] . Although apoptosis can be activated in response to noxious stimuli, e.g., starvation, inflammation, infection, and irradiation, recent data suggest an active physiological role for apoptosis. These include the control of tissue development and differentiation, regulation of mitogenic effects, and control of cell death and loss of tissue with aging [4] . Dysregulation of apoptotic cell death has been implicated in states of disease and in the neoplastic transformation [1] [2] [3] [4] [5] .
Among the pro-apoptotic systems that operate in epithelial tissues [6] , the P2X 7 mechanism is probably the most important because the P2X 7 receptor is expressed mainly by proliferating epithelial cells [7] , thereby controlling directly the growth of epithelia. The P2X 7 receptor is a membrane-bound, ligand-operated channel whose main function in epithelial cells is mediation of apoptosis [8] [9] [10] . The natural ligand of the P2X 7 receptor is adenosine triphosphate (ATP) [8, 9] , which is present in the extracellular fluid of epithelial cells at high nanomolar and low micromolar levels [11] [12] [13] [14] [15] . While ATP requirements of the P2X 7 receptor are higher than those of other purinergic receptors [8, 9] , the ATP levels in extracellular fluids suffice to activate the receptor [15] . Activation by ATP can stimulate different signaling pathways including the IL-1β [16] , TNFα-TRAIL [17] , and the p38, JNK/ SAPK [18] , and NF-κB cascades [19] , some of which can induce apoptosis. The quantitatively significant proapoptotic ATP/P2X 7 effect in epithelial cells involves formation of pores in the plasma membrane [6, 15, 20] , and uncontrolled influx of Ca 2+ via P2X 7 pores induces apoptosis by the mitochondrial-caspase-9 pathway [6, 15] .
P2X 7 pore formation involves formation of channels composed of pannexins [21, 22] and ectodomains of the P2X 7 molecule [20, 23] , and it depends on ligand (ATP) availability, expression in the plasma membrane of the functional (glycosylated) full-length receptor, homo(tri)-oligomerization of the functional full-length receptor [8] [9] [10] , and the presence of P2X 7 splice variants [20] . P2X 7 molecules can hetero-oligomerize with other types of P2 purinergic receptor molecules [24] , but it is unknown whether these interactions result in the formation of pores. In contrast, P2X 7 molecules can hetero-oligomerize with truncated and other P2X 7 splice variant molecules, thereby forming non-functional oligomers that prevent formation of functional pores [20] .
Central to the ability of ATP to induce apoptosis via the P2X 7 pore mechanism is the degree of cellular expression of the P2X 7 receptor [10] . Plasma membrane expression of the P2X 7 receptor depends on the rates of transcription and P2X 7 messenger RNA (mRNA) degradation [25] ; receptor glycosylation [26, 27] , trafficking, and sorting to the plasma membrane [26] ; and on receptor turnover as determined by internalization, degradation, and recycling [26] . Liganddependent activation of the receptor induces GRK-3, β-arrestin-2, dynamin-dependent internalization into clathrin domains, and receptor recycling into the plasma membrane [26] .
The question of P2X 7 receptor expression in cancer epithelial cells and whether changes in expression play a role in cancer development were raised already a decade ago (e.g., [28] ), usually in the context of biomarker research (e.g., [29] ). Earlier studies reported lower levels of the receptor in non-melanoma skin cancer than in normal tissues [28] , but higher levels of the receptor in breast cancers [30] melanoma [29] and prostate cancers [31] than in normal tissues. However, the significance of these findings is unclear since some of the studies used methods that could have detected non-functional P2X 7 receptors. For instance, Barden et al. [29] [30] [31] [32] assayed P2X 7 immunoreactivity with rabbit anti-P2X 7 antibody raised against epitope C200-C216 of the human P2X 7 receptor. This epitope is located in the extracellular loop of the protein, and the antibody is likely to detect both the full-length functional receptor as well as variants lacking the C-terminus [20] , which is critical for P2X 7 mediation of apoptosis [20] . Variants lacking the C-terminus are non-functional [20] , and since the expression of some variants lacking the C-terminus is exceptionally high in cancer cells [20] , assays using that antibody may have overestimated expression of the P2X 7 receptor in cancer cells by detecting predominantly non-functional receptors.
Recent studies employing methods that used anti-P2X 7 antibodies raised against epitopes located in the C-terminus showed lower P2X 7 expression and lesser P2X 7 -dependent apoptosis in uterine epithelial cancer cells than in normal uterine epithelial cells [7, 20, 25, 33] . But a more recent study reported higher levels of the P2X 7 receptor in thyroid papillary cancer cells than in normal thyroid cells [34] .
In view of the importance of apoptosis-related mechanisms for epithelial cancer development [35] [36] [37] and the discrepancy in reports of P2X 7 receptor levels in epithelial cancer cells among different studies, a comprehensive study was undertaken to answer some of these questions. The main objective of the study was to improve our understanding of the biological role of the P2X 7 in the genesis and development of epithelial cancers. The principles of the study were as follows: (a) detection of P2X 7 receptor by immunostaining, using a commercially available, wellcharacterized anti-P2X 7 receptor antibodies that react with the functional P2X 7 receptor; (b) quantification of P2X 7 receptor immunofluorescence in preserved tissues, in situ, by image capturing and analysis; (c) comparison of P2X 7 receptor levels in epithelial cancer cells with those of the corresponding epithelial normal cells of the same tissue in the same surgical specimen (i.e., the same patient); (d) comparison of data obtained by P2X 7 receptor immunofluorescence with the data obtained by P2X 7 receptor horseradish peroxidase (HRP) immunostaining with diaminobenzidine (DAB); (e) for selected types of epithelial cancers, analysis of P2X 7 receptor levels in dysplastic, precancerous, and early stages of the cancer and comparison with the levels in the normal cells of the same surgical specimen; and (f) for selected types of epithelial cancers, confirmation of the P2X 7 receptor (protein) findings with P2X 7 mRNA assays.
Experimental procedures

Human tissues
Discarded human tissues for P2X 7 receptor (protein) assays were obtained after approval of the research protocol by the Institutional Review Boards from the Human Tissue Procurement Facility of University Hospital CASE Medical Center, Case Western Reserve University, Cleveland, Ohio, and the University of Toledo Medical Center, Toledo, Ohio. Cross sections of tissue segments were obtained from paraffin-embedded blocks that were prepared by the Departments of Pathology initially to establish the patient's diagnosis. For the purpose of the present study, additional parallel 5-µm sections were cut and slides intended for immunostaining were made by the Departments of Pathology according to standard procedures. This part of the study included tissues obtained from 88 patients (72 women and 16 men; Table 1 ). Included in each case were cross sections of the cancer tissue and an adjacent histologically normal tissue.
Discarded human tissues for mRNA assays were obtained after approval of the research protocol by the Institutional Review Board from the Department of Pathology at the Ohio State University, Columbus, Ohio, through the Cooperative Human Tissue Network (National Cancer Institute). Tissues were snap-frozen in liquid N 2 , shipped on dry ice, and stored at −80°C until assayed. Included were tissues obtained from 19 patients (18 women and one man; Table 1 ). Included in each case were blocks of the cancer tissue and an adjacent histologically normal tissue.
The histological diagnoses presented below were made by the Departments of Pathology at the University Hospital CASE Medical Center, the University of Toledo Medical Center, and the Ohio State University and were provided to the research team prior to assays. No attempt was made to categorize results by patients' gender, age, or ethnic and race origin.
Protein methods
The receptor P2X 7 was detected immunologically as described [7, 33] , using either the Alomone rabbit polyclonal anti-P2X 7 receptor antibody (Alomone Laboratories, Jerusalem, Israel) [7, 20, [25] [26] [27] 33] or the rabbit anti-P2X 7 R Sigma antibody (Sigma Chemical, St. Louis, MO, USA, Cat # P-8232, Lot # 047K1346), in the absence or presence of the antigen peptide. Both antibodies were raised against an immunogenic peptide corresponding to amino acids 576-595 of the rat P2X 7 (with an additional Nterminal cysteine), which represents an epitope that is highly conserved in mouse and human P2X 7 [38, 39] . Both antibodies target immunogenic domains at the C-terminus of the receptor and recognize the functional full-length P2X 7 receptor [20] . Previous immunostaining studies using the Alomone or Sigma rabbit polyclonal anti-P2X 7 receptor antibodies in cultured epithelial cells [6, 7, 15, 20, 26, 27] and in vivo [7, 33] revealed that both antibodies immunoreacted with the functional full-length P2X 7 [7, 33] . For HRP immunostaining with DAB, paraffin tissue cross sections mounted on glass slides were deparaffinized with xylenes, rehydrated with serial ethanols in water (100-0%), washed with phosphate-buffered saline (PBS), and boiled in 10 mM citric acid buffer, pH 6.0 for 10 min. Slides were immersed in 3% bovine serum albumin/1% Triton X-100 for 60 min at room temperature to block nonspecific background, and sections were incubated overnight at 4°C in a humidified chamber dark with 1:50 rabbit anti-P2X 7 R antibody. Following washes with PBS, sections were incubated with HRP-labeled anti-rabbit IgG (H+L) antibody (Jackson ImmunoResearch Cat # 211-035-109) at 1:500 for 1 h at room temperature in the dark. The reaction was developed using peroxidase substratebkit DAB (Vector, Cat # SK-4100) for 5 min at room temperature; sections were washed with PBS and water, counterstained with hematoxylin for 30 s, washed in water, dehydrated with serial ethanol, and cleared with xylene. Coverslips were mounted using permanent mounting medium, and pictures were captured by light microscopy.
The method of image analysis of immunofluorescence data was described [7, 33] . Briefly, tissue cross sections were analyzed under a fluorescence microscope Nikon Eclipse 80i (Nikon, Melville, NY, USA). Fields of interest were captured and saved in Adobe Photoshop. Pictures were scanned using UN-SCAN-IT software (Silk Scientific, Orem, UT, USA) by choosing three to five representative fields for each picture. Fields of interest were chosen in reference to the epithelial component of the tissue, as determined by co-immunostaining with E-cadherin or CK-18 ([33] ; Fig. 1a, b) . Light intensity in each field (usually at ×10 magnification) was digitized, and average pixel density for P2X 7 per field was determined using the program software. For each clinical case, average data of P2X 7 pixel density in the histologically diagnosed abnormal regions were normalized to the average P2X 7 pixel density of the histologically diagnosed normal region.
Real-time quantitative polymerase chain reaction Total RNA from tissues was extracted by RNeasy mini kit (Qiagen, Valencia, CA, USA), and one-step real-time quantitative polymerase chain reaction (qPCR) was carried out as described [33] . Primers for the P2X 7 , E-cadherin, and CK-18 (for data normalization per epithelial mass) and PCR conditions were described [7, 20, 33] . E-cadherin was used for assays with ectocervical tissues, and CK-18 was used for assays with endocervical, endometrial, bladder, and breast tissues. Relative quantification (RQ) was calculated using Applied Biosystems SDS software (Foster City, CA, USA) based on the equation RQ ¼ 2
ÀΔΔCt where C t is the threshold cycle to detect fluorescence. For each clinical case, P2X 7 /E-cadherin mRNA or P2X 7 /CK-18 mRNA levels in the histologically diagnosed abnormal regions were normalized to the P2X 7 /E-cadherin mRNA or P2X 7 /CK-18 mRNA levels of the histologically diagnosed normal region (all assays in triplicates).
Data analysis
Data were analyzed using GraphPad Instat, GraphPad Software Inc., San Diego, CA, USA. Significance of differences among groups was estimated by paired t test and Mann-Whitney analysis.
Supplies
All chemicals, unless specified otherwise, were obtained from Sigma Chemical (St. Louis, MO, USA).
Results
Validation of the P2X 7 immunostaining methods
For immunofluorescence assays, the epithelial component of the tissues was identified by staining with the anti-E-cadherin (or anti-cytokeratin-18) antibodies (Fig. 1a) . Co-staining with the anti-P2X 7 antibody revealed immunoreactivity localized foremost with the epithelial component of the tissue (Fig. 1b) . The P2X 7 immunoreactivity was blocked when tissues were co-incubated with the P2X 7 antigen (Fig. 1c) .
The intensity of the P2X 7 immunoreactivity signal differed by the presence of abnormal cells. For instance, in the example of urinary bladder cross section shown in Fig. 1a -c, containing both normal and transitional cell cancer tissues, the anti-P2X 7 antibody reacted with both the normal and the cancerous cells. However, the P2X 7 immunofluorescence of normal cells was stronger than that of the cancer cells (Fig. 1b) , and quantification revealed that the P2X 7 immunofluorescence in the cancer cells was weaker, at only 0.55-fold of that in the normal cells.
Data obtained by P2X 7 receptor immunofluorescence were compared with those obtained by P2X 7 receptor HRP-DAB immunostaining and the results were similar. For example, in the cross section of thyroid tissue shown in Fig. 1e , containing both normal and papillary cancer tissue, the P2X 7 immunofluorescence in the cancer cells was 1.35-fold stronger than the P2X 7 immunofluorescence in the normal cells. In a parallel section cut from the same specimen, P2X 7 receptor HRP-DAB immunostaining showed a similar trend (Fig. 1f) . These data validate the specificity of either method to detect P2X 7 immunoreactivity in tissue cross sections in situ. However, since immunofluorescence assays proved to have greater sensitivity and the advantage of double staining with an epithelial marker (E-cadherin or CK-18), they were used as the main method for quantification of P2X 7 immunoreactivity.
The cellular compartmentalization of the P2X 7 immunoreactivity depended on the type of cell that was studied and on its state of differentiation. P2X 7 immunoreactivity could be detected at cell regions of the plasma membrane, cytoplasm, perinuclear, and occasionally in nuclear regions (see below). In the example of the uterine epithelium, high magnification of cross sections of early proliferative endometrial glands demonstrated diffuse P2X 7 immunoreactivity in the cytoplasm, perinuclear regions, and plasma membranes, with minimal nuclear staining (Fig. 1g) . In cross sections of endometrial glands at more advanced stage of maturation (i.e., mid-late proliferative phases), the P2X 7 immunoreactivity in apical (luminal) plasma membrane regions increased, while the P2X 7 immunoreactivity in the basolateral regions of the plasma membrane and in the cytoplasm and perinuclear regions remained stable ( Fig. 1h-j) . A similar effect of predominantly apical localization of the P2X 7 receptor was described in ectocervical epithelial cells [40] . In contrast, in the colonic epithelium, P2X 7 receptor expression was equally distributed in the apical and basolateral regions of the plasma membrane (not shown). Fig. 1 a-c Co-immunostaining of bladder cross section, containing normal (N) and transitional cell carcinoma tissues (Ca), with anti-E-cadherin antibody (Ab; a), and anti-P2X 7 antibody in the absence (b) or presence (c) of the P2X 7 antigen (Ag). The specific P2X 7 immunoreactivity of cancer cells was 0.55-fold weaker than that of the normal cells. Magnification ×10. d-f. Cross section of thyroid, containing normal (N) and papillary carcinoma tissues (Ca), stained with H&E (d); coimmunostained with anti-P2X 7 antibody (green), anticytokeratin-18 antibody (red), and with DAPI (nuclear stain, blue) and evaluated by immunofluorescence (e); or immunostained with anti-P2X 7 antibody by HRP-DAB method (f). The P2X 7 immunoreactivity of cancer cells in e was 1.35-fold stronger than that of the normal cells, and the P2X 7 immunoreactivity by HRP-DAB immunostaining showed a similar trend (f). Magnification ×10. g-j Immunostaining with anti-P2X 7 antibody of endometrial glands cross sections obtained from women at different phases of the menstrual cycle. Magnification ×20 P2X 7 receptor levels in normal and cancer epithelial cells Levels of P2X 7 receptor were evaluated in situ in normal and cancer epithelial cells of the following seven tissues: ectocervix, endocervix, endometrium, urinary bladder, breast, colon, and thyroid. In some tissues (ectocervix, endometrium, and bladder), assays evaluated P2X 7 receptor levels also in hyperplastic, dysplasia, pre-cancerous, and early stage cancer cells. In all cases, the histological diagnoses were provided to the research team prior to the P2X 7 assays. Included in the study were specimens (one per patient) that included both the normal and abnormal tissue, sometimes within the same microscopical field. For each clinical case (i.e., patient), cross sections including the normal and abnormal tissues were mounted on the same glass slide and were assayed simultaneously. Since the focus of the study was to better understand the biological role of the P2X 7 in the genesis and development of epithelial cancers rather than biomarker assays, in each clinical case, data of epithelial P2X 7 Ectocervix In cross sections of the normal ectocervix, P2X 7 immunoreactivity was found mainly in the epithelial cells, and it was prominent in cells of the basal/parabasal layers (i.e., the proliferating cells; e.g., Figs. 2a, e and 6a). The staining was usually weaker in cells of the intermediate layers and stronger in the superficial layers (Figs. 2a, e and 6a) . In most cases, staining was found in the cytoplasm and plasma membrane, with moderate nuclear staining (e.g., Fig. 2a) . In some cases, the nuclear staining was minimal (e.g., Fig. 2i ). In dysplastic and squamous carcinoma cells, the weak P2X 7 immunoreactivity was distributed throughout the cell (Fig. 2c, g, and k) . Sixteen clinical cases were studied, including three mild-moderate dysplasias, three moderate-severe (high-grade) dysplasias, and ten squamous cell carcinomas (Table 1) . Ten cases (all dysplasias and four cancers) were evaluated by P2X 7 receptor immunofluorescence, four cancer cases by P2X 7 receptor HRP-DAB immunostaining, and one cancer case was evaluated both by the immunofluorescence and HRP-DAB immunostaining methods. In cases of cervical dysplasia, P2X 7 receptor levels were lower in dysplastic cells compared to normal cells, regardless of the degree of dysplasia (e.g., Fig. 2a , c, e, and g). In those cases, the mean ratio (± SD) of mildmoderate dysplasia/normal P2X 7 receptor levels was 0.46± 0.15 (Fig. 7a, p<0 .01, compared to normal), and the mean ratio of moderate-severe dysplasia/normal P2X 7 receptor levels was 0.40±0.18 (Fig. 7b, p<0.01) . In all cancer cases evaluated by immunofluorescence, epithelial cell P2X 7 receptor levels were lower in the cancer cells than in the normal cells (e.g., Fig. 2i, k) , and the mean ratio of cancer/ normal P2X 7 receptor levels was 0.45±0.16 (Fig. 7c , p< 0.01). Similar results were obtained in the cases that were evaluated by HRP-DAB immunostaining (e.g., Fig. 6a, b) .
Endocervix In cross sections of the normal endocervix, P2X 7 immunoreactivity was found mainly in epithelial cells composing the endocervical crypt, and it was localized in the cytoplasm and plasma membrane, with minimalmoderate nuclear staining (Fig. 2m) . A similar pattern was found in tissues with endocervical adenocarcinoma (Fig. 2o) . Three cases of endocervical adenocarcinoma were evaluated by P2X 7 receptor immunofluorescence ( Table 1) . In all cases, epithelial cell P2X 7 receptor levels were lower in the cancer cells than those in the normal cells (e.g., Fig. 2m, n) , and the mean ratio of cancer/normal P2X 7 receptor levels was 0.52±0.07 (Fig. 7d, p<0 .01).
Endometrium In cross sections of the normal endometrium, P2X 7 immunoreactivity was found mainly in epithelial cells composing the endometrial glands (Figs. 3a, e, i, n and 6c, d) . Immunoreactivity was found in the cytoplasm and plasma membrane, with minimal nuclear staining, but the most prominent staining was found in apical cytoplasmic/plasma membrane regions of the cells (Figs. 3e, n and 6c, d) . A similar pattern was found in tissues with endometrial simple (Fig. 3c ) and complex hyperplasia (Fig. 3g) . A similar pattern was also found in tissues with endometrial complex hyperplasia with atypia ( Fig. 3k ) and endometrial adenocarcinoma (Figs. 3n and 6c, d ), but the prominent apical glandular hyperstaining was lost. Twenty-two cases were studied, including eight cases of benign hyperplasia (five simple and three complex hyperplasia without atypia), five cases of the pre-cancerous complex hyperplasia with atypia, and nine endometrial carcinomas (all type 1 endometrioid adenocarcinomas; Table 1 ). Nineteen cases (all benign hyperplastic and pre-cancerous cases and six cancers) were evaluated by P2X 7 receptor immunofluorescence; one cancer case was evaluated by the P2X 7 receptor HRP-DAB immunostaining method, and one cancer case was evaluated by both the immunofluorescence and HRP-DAB immunostaining methods. In all cases of benign hyperplasia, P2X 7 receptor levels were similar to those in normal cells (e.g., Fig. 3a , c, e, and g) with a mean ratio of hyperplasia/normal P2X 7 receptor levels of 1.01±0.06 (Fig. 7e, p>0.8) . In contrast, in all cases of complex hyperplasia with atypia, P2X 7 receptor levels were lower in the abnormal cells compared to the normal cells (e.g., Fig. 3i, k) , and in those cases, the mean ratio of abnormal/ normal P2X 7 receptor levels was 0.39±0.10 (Fig. 7f, p<  0.01) . In all cancer cases evaluated by immunofluores-cence, epithelial cell P2X 7 receptor levels were lower in the cancer cells than in the normal cells (e.g., Fig. 3m , n) with a mean ratio of cancer/normal P2X 7 receptor levels of 0.40± 0.12 (Fig. 7g, p<0.01) . Similar results were obtained in cancer cases that were evaluated by HRP-DAB immunostaining (e.g., Fig. 6c, d ).
Urinary bladder
In cross sections of the normal urinary bladder, P2X 7 immunoreactivity was found mainly in the transitional epithelial cells, and it was more prominent in cells resting on the basal membrane (i.e., the proliferating cells; Figs. 1b and 4a) . The strongest staining was found in perinuclear regions, but immunoreactivity was also found The dysplasia occupies about one half of the thickness of the epithelium (double-pointed arrow). g, h The dysplasia occupies the entire thickness of the epithelium, engulfing an island of histologically appearing normal granular superficial cells (left-pointed arrow). Magnification ×10. Data are summarized in Fig. 7 in the cytoplasm and plasma membrane, with minimalmoderate nuclear staining. A similar pattern was also found in tissues with transitional cell carcinoma in situ (Fig. 4c, g ), and with invasive transitional cell carcinomas (Fig. 4k, o) . Twenty-two clinical cases were studied, including ten invasive transitional cell carcinomas, and 12 cases of transitional cell carcinoma in situ (Table 1 ). All cases were evaluated by P2X 7 receptor immunofluorescence immunostaining. In ten of the 12 cases of transitional cell carcinoma in situ, P2X 7 receptor levels were lower in the cancer cells than in the normal cells (e.g., Figs. 4a, c, e and 7i), while in two cases P2X 7 receptor levels were higher in the carcinoma in situ cells than in the normal cells (Fig. 7i) . However, for the entire transitional cell carcinoma in situ group, the mean ratio of cancer/normal P2X 7 receptor levels was 0.77±0.15 (Fig. 7i, p<0.01) . In all cases of invasive transitional cell carcinoma, epithelial cell P2X 7 receptor levels were lower in the cancer cells than in the normal cells (e.g., Fig. 4i, k, m, and o) , and the mean ratio of cancer/normal P2X 7 receptor levels was 0.48±0.15 (Fig. 7j, p<0 .01).
Breast In cross sections of the normal breast, P2X 7 immunoreactivity in ductal and lobular tissues was localized mainly in perinuclear regions and the plasma membrane, with minimal nuclear staining (Fig. 5a , e, and i). In breast ductal or lobular carcinoma cells, the P2X 7 immunoreactivity was distributed throughout the cells, with minimal nuclear staining (Fig. 5c, g, and k) . Sixteen clinical cases were studied, including 13 invasive ductal carcinomas and three invasive lobular carcinomas (Table 1) . Fourteen cases were evaluated by P2X 7 receptor immuno- Fig. 3 P2X 7 and E-cadherin immunoreactivities (by immunofluorescence) in cross sections of normal endometrium and of endometrium containing simple hyperplasia, complex hyperplasia, complex hyperplasia with atypia, and adenocarcinoma (a-n). Each of the four panels (a-d, e-h, i-l) shows normal and hyperplasia/cancer tissues obtained from the same patient. m, n Cross sections containing both normal endometrial glands (upper part, N) and adenocarcinomatous glands (lower part, Ca). Magnification ×10. Data are summarized in Fig. 7 fluorescence immunostaining and two by the P2X 7 receptor HRP-DAB immunostaining method. In seven of the 12 invasive ductal carcinomas, P2X 7 receptor levels were lower in the cancer cells than in the normal cells (e.g., Figs. 5a, c, e, g and 7h); in three cases of the 12 invasive ductal carcinomas, P2X 7 receptor levels were similar in the cancer and normal cells (Fig. 7h) , and in two cases, P2X 7 receptor levels were higher in the cancer cells than in the normal cells (Fig. 7h) . In all three invasive lobular carcinomas, P2X 7 receptor levels were lower in the cancer cells than in the normal cells (e.g., Fig. 5i, k) . For the entire breast group, the mean ratio of cancer/normal P2X 7 receptor levels was 0.67±0.33 (Fig. 7h, p<0.01 ). In the two invasive ductal carcinoma cases that were evaluated by HRP-DAB immunostaining, P2X 7 receptor levels were lower in the cancer cells than in the normal cells (e.g., Fig. 6e, f) .
Colon In cross sections of the normal colon, P2X 7 immunoreactivity was localized mainly in the basolateral aspect of the mucosal cells, with minimal nuclear staining (Fig. 5m) . In colon adenocarcinoma cells, the P2X 7 immunoreactivity was distributed throughout the cells, but it was predominantly cytoplasmic with minimal nuclear staining (Fig. 5o) . Five clinical cases of adenocarcinoma were studied (Table 1) , all by P2X 7 receptor immunofluo- Each of the four panels (a-d, e-h, i-j, m-p) shows normal and CIS or cancer tissues obtained from the same patient. Magnification ×10. Data are summarized in Fig. 7 rescence immunostaining. In all five cases, P2X 7 receptor levels were similar in the cancer cells and the normal cells (e.g., Fig. 5m , o, and q), with a mean ratio of cancer/normal P2X 7 receptor levels of 0.99±0.05 (Fig. 7k, p>0.9 ).
Thyroid In cross sections of the normal thyroid, P2X 7 immunoreactivity was localized mainly within thyrocytes bordering the follicles (Figs. 1e, 5s, u, and 6g, h) ; the immunoreactivity was most prominent at perinuclear Each of the six panels (a-d, e-h, i-l, m-p, q-r, s-v) shows normal and cancer tissues obtained from the same patient. q, r, s, t, u, v Cross sections containing both normal (left-pointed arrows) and cancerous tissues (right-pointed arrows). Magnification ×10. Data are summarized in Fig. 7 regions, but it was also found in the cytoplasm and plasma membrane regions (e.g., Fig. 5s ). In thyroid papillary cancer cells, the P2X 7 immunoreactivity was distributed throughout the cells, with minimal nuclear staining (Figs. 5s, u and 6g, h) . Four clinical cases of papillary carcinoma were studied (Table 1) , all evaluated both by P2X 7 receptor immunofluorescence immunostaining and the P2X 7 receptor HRP-DAB immunostaining method. In all cases, P2X 7 receptor levels were higher in the cancer cells than in the normal cells (Fig. 5s, u) , with a mean ratio of cancer/normal P2X 7 receptor levels of 1.26 ± 0.16 (Fig. 7l, p<0.01) . Similar results were obtained in the cancer cases that were evaluated by HRP-DAB immunostaining (e.g., Fig. 6g, h ). Fig. 6 P2X 7 immunoreactivity detected by HRP-DAB immunostaining (brown color), in cross sections of normal (a) and squamous cell carcinoma cervical tissues (b); endometrial tissues (c, d) containing both normal glands (N) and adenocarcinomatous glands (Ca); breast tissues (e, f) containing both normal ducts and ductal adenocarcinomatous tissues; and thyroid tissues (g, h) containing both normal and papillary carcinoma tissues. Magnification ×10 Fig. 7 a- In summary, assays using two different immunostaining methods with anti-P2X 7 receptor antibodies that immunoreact with the functional, full-length P2X 7 receptor revealed lower levels of the P2X 7 receptor in ectocervical squamous cell carcinoma, endocervical and endometrial adenocarcinoma, bladder transitional cell carcinoma, and breast ductal and lobular carcinoma cells, than in the corresponding normal epithelial cells. In addition, P2X 7 receptor levels were lower also in dysplastic, pre-cancerous, and early cancerous epithelial cells of the ectocervix, endometrium, and bladder, compared to the corresponding normal epithelial cells. In thyroid papillary carcinoma cells, P2X 7 receptor levels were higher than in the corresponding normal epithelial cells, while P2X 7 receptor levels were similar in normal colon and adenocarcinoma epithelial cells.
P2X 7 mRNA levels in normal and cancer epithelial cells
To better understand the mechanism that leads to lower levels of the P2X 7 receptor in the uterine, bladder, and breast cancer epithelial cells, levels of P2X 7 mRNA were determined. For each clinical case (i.e., patient), minces containing the normal and abnormal tissues were processed and assayed simultaneously for P2X 7 mRNA steady-state levels by real-time qPCR (Table 1) . C t values (corresponding to total P2X 7 mRNA in the specimen) were normalized to E-cadherin mRNA (ectocervix and breast), or to cytokeratin-18 (CK-18) mRNA (endocervix, endometrium, and bladder) to determine the epithelium-related P2X 7 mRNA [33] . For each clinical case, data of epithelial P2X 7 mRNA levels in cancer tissues were normalized to those of normal cells.
For all five studied epithelia, P2X 7 mRNA steady-state levels were lower in the epithelial cancer component than in the normal epithelial tissues. Thus, the mean ratios of P2X 7 / E-cadherin mRNA levels in cancer versus normal ectocervix and breast were 0.19±0.08 and 0.51±0.12, respectively (Fig. 8, p<0 .01 [compared to normals]), and the mean ratios of P2X 7 /CK-18 mRNA levels in cancer versus normal endocervix, endometrium, and bladder were 0.27± 0.14, 0.16±0.06, and 0.08±0.06, respectively (Fig. 8 , p< 0.01 [compared to normals]). These data indicate that in uterine, bladder, and breast cancer epithelial cells, low P2X 7 receptor levels correlate with low P2X 7 mRNA levels. Moreover, in those epithelia, the decrease of P2X 7 mRNA in cancer cells was quantitatively greater than that of the P2X 7 receptor.
Discussion
The main objective of the study was to better understand the biological role of P2X 7 in the genesis and development of epithelial cancers. The main findings were as follows: (a) Expression levels of the functional, full-length P2X 7 receptor in epithelial cancers are cell-type specific; (b) in uterine, bladder, and breast epithelial cancer cells, P2X 7 receptor and mRNA levels were lower than in the corresponding normal epithelial cells; (c) in the ectocervix endometrium and bladder, P2X 7 receptor levels were lower also in dysplastic, pre-cancerous, and early cancerous epithelial cells; and (d) P2X 7 receptor levels were higher in thyroid papillary carcinoma cells than in the corresponding normal epithelial cells and similar in colon adenocarcinoma and the corresponding normal epithelial cells.
The present data were obtained by two complementary immunostaining methods: immunofluorescence, which is more sensitive in capturing signals and therefore more amenable to quantification, and HRP-DAB which allows easier identification of tissue structural components. Data were similar regardless of the method used.
One of our objectives was to ascertain that the measured P2X 7 immunoreactivity reflects binding of the anti-P2X 7 receptor antibody to the functional form of the receptor. This is important for proper evaluation of the results, given the fact that conclusions of previous studies by others may have been influenced by the identification also of nonfunctional receptor(s). P2X 7 receptor polymorphism in reference to the functional full-length human P2X 7 (GeneBank accession number Y09561) involves mutated forms and variants (reviewed in [20] ). All polymorphic forms resulting from point mutations can immunoreact with the presently used anti-P2X 7 receptor antibodies and provide theoretically inaccurate determinations for the expression of the functional P2X 7 receptor. However, studies in the lab found that the prevalence of normal or cancer cells bearing single nucleotide polymorphic forms in various epithelial tissues was low (not shown). Therefore, quantitatively, the presence of such forms should have had only a negligible effect on P2X 7 immunoreactivity with the use of the current anti-P2X 7 receptor antibodies.
In contrast and of greater concern are truncated variants of the human P2X 7 receptor, resulting from alternative splicing [20, 41, 42] that lack the carboxy terminus of the wild-type P2X 7 receptor. Since the carboxy terminus is essential for P2X 7 receptor-mediated apoptosis [20] , these forms are non-functional. Of particular importance is the truncated P2X 7-j isoform [20] that is prevalent in epithelial cancers including uterine [20] , breast, bladder, skin, colon, and prostate (not shown). It is expressed in cancer epithelial cells at relatively high concentrations [20] , and the expression ratio of the P2X 7-j form compared to the fulllength P2X 7 receptor is significantly higher in cancer epithelial cells than in the corresponding normal epithelial cells [20] . The P2X 7-j form is ineffective when expressed alone [20] . Moreover, when co-expressed with the functional full-length P2X 7 receptor, it can oligomerize and render it ineffective [20] . We therefore utilized anti-P2X 7 receptor antibodies that bind the full-length form but not truncated isoform(s) lacking the carboxy terminus of the receptor. These antibodies were previously shown to specifically interact with the functional full-length receptor, with only minimal influence by the expression of the P2X 7-j variant [20, 26] .
Depending on the type of cell that was studied, P2X 7 immunoreactivity could be found in different cellular locations. Co-localization with plasma membrane domains reflects the full-length, glycosylated active receptor inserted in the plasma membrane [20, 26] . P2X 7 immunoreactivity found in the cytoplasm may reflect newly formed receptor en route to be inserted into the plasma membrane, or postactivation internalized, degraded, or recycled receptor [20] . Perinuclear/nuclear P2X 7 immunoreactivity was previously described in epithelial [28, 43, 44] and other types of cells [45, 46] , but its biological significance remains unclear. It is unlikely an artifact (i.e., non-specific binding) because it was found in tissues processed in parallel with those not found to express this type of signal (present study).
The present data in uterine epithelia confirmed previous reports [7, 33] , with the novelty of presenting a more comprehensive and unified quantitative analysis and comparing data of P2X 7 immunofluorescence with P2X 7 HRP-DAB immunostaining. The data in normal endometrial glands also showed for the first time sorting of the P2X 7 receptor into apical domains of the plasma membrane, and the effect depended on the level of tissue differentiation. Accordingly, the degree of P2X 7 receptor sorting into apical regions of the plasma membrane was greatest in tissues of women at the late proliferative phase of the menstrual cycle ( Fig. 1g-j) . Previous studies also reported preferential sorting of the P2X 7 receptor into apical domains of the plasma membrane in cervical epithelial cells [40] , as well as of other purinergic receptors (P2Y 2 and P2X 4 [47] [48] [49] [50] ). However, the biological significance of these findings is at present unclear.
The data in urinary bladder epithelial cells are novel, and they showed similar trends of lower P2X 7 receptor expression in cancer than in normal epithelial cells. Our data of higher P2X 7 receptor expression in thyroid papillary cancer cells than in normal thyroid epithelial cells confirm a recent report by Solini et al. [34] .
The present breast data differ from those previously reported by Slater et al. [30] . The latter reported that normal and mildly hyperplastic breast epithelia were devoid of the P2X 7 receptor, whereas epithelial cells of in situ or invasive lobular or ductal carcinoma were labeled intensely. However, the assay used by Slater et al. [30] most likely identified non-functional splice variant(s) of the receptor [32] . The focus of the present study was evaluation of expression of the functional, full-length receptor, which mediates the apoptosis. Our data in normal breast tissues showed extensive expression of the functional P2X 7 receptor in ducts and acini (Fig. 5 ) and lowered expression in ductal and lobular cancer epithelial cells (Fig. 7h) . Therefore, the most likely explanation for the differences between the present data and those of Slater et al. [30] is that normal breast epithelial cells express predominantly the functional full-length P2X 7 receptor, and that the expression of the receptor is decreased in cancer cells. In contrast, cancer cells express predominantly non-active variant(s), similar to previously reported data in the uterus [20] . The expression pattern of P2X 7 receptors in other types of epithelial cancers is at present unknown. Using a method that detected also non-functional receptor(s), Slater et al. [31] reported that P2X 7 receptors were absent from normal prostate epithelium, but were present in prostate cancers. However, P2X 7 immunoreactivity was present in apparently normal epithelial cells in acini well outside the tumor margins. Similarly, this group also reported extensive P2X 7 immunoreactivity in areas affected by spreading skin melanoma cells which extended 2 µm from the melanoma into the keratinocyte layer of the adjacent normal epidermis [29] . In view of the above discussion, those data need to be confirmed using assays that detect the functional form of the receptor.
A different trend, resembling that found by us in the uterus, bladder, and breast, was found by Greig et al. [28] in non-melanoma skin lesions. Their assay included the use of a polyclonal anti-P2X 7 receptor antibody raised against antigenic domain in the C-terminus of the receptor [51] . P2X 7 receptors were expressed in the stratum corneum of the epidermis, but only weakly in occasional squamous carcinoma cells and in necrotic regions within basal cell carcinoma tumors. In those tissues, the P2X 7 immunoreactivity co-localized with TUNEL labeling [28] . Their analysis of P2X 7 expression in different subgroups of basal cell carcinomas suggested that in moderately aggressive tumors there was a high level of expression of P2X 7 receptors, but with increasing aggressiveness of tumor this trend was reduced. Since apoptosis plays an important role in the tumorigenesis of basal cell carcinoma [28] , the authors proposed that the loss of P2X 7 receptor expression could lead to increased tumor aggressiveness [28] .
While our data in the uterus, bladder, and breast resemble those of Greig et al. [28] , there is a fundamental difference between the results as they relate to the localization of P2X 7 immunoreactivity in normal stratifying epithelia. Stratified epithelia are composed of proliferating and regenerating cells of the basal layer which rest on the basal membrane and continue to divide throughout life. In the skin, a large pool of reserve cells can be also found in proliferating cells within hair shafts. Daughter cells in the parabasal layers differentiate into polyhedral cells that are most active in protein synthesis [52] and express early differentiation markers. Superficial to the parabasal layer are the granular layer of metabolically active cells, and the transitional layer of still living cells with evidence of early stages of terminal differentiation. The skin, in contrast to non-keratinizing stratified epithelia (e.g., the cervix), also contains the superficial stratum corneum, composed of layer(s) of flat dead cells [53] .
The skin data of Greig et al. [28] identified intense P2X 7 immunoreactivity in the granular and transitional layers and in the stratum corneum. In contrast, they reported low P2X 7 immunoreactivity in basal/parabasal layers and only occasionally in hair follicles and mature hair shafts [28] . Similarly, in the non-keratinizing stratified epithelia of the cornea and esophagus, the authors found only little or no P2X 7 immunoreactivity [28] . Contrary to their findings, recent data [7, 33] and the present study localized intense P2X 7 immunoreactivity in human stratified epithelia in basal/parabasal layers (e.g., Fig. 2a) . Our experiments, which probably utilized a more sensitive assay than that of Greig et al. also showed lesser expression in the intermediate ectocervical layers of the epithelium (equivalent to the epidermal granular layers) and more intense immunoreactivity in the superficial layers ( [7] ; Fig. 2a, e) . The explanation to this undulant pattern of P2X 7 immunoreactivity is provided by the recent in situ hybridization assays in the normal human ectocervical epithelium [7] . The data showed that P2X 7 mRNA localized foremost to the basal/ parabasal layers [7] , in correlation with the intense P2X 7 immunoreactivity in those layers (Fig. 2a, e) . In contrast, the P2X 7 immunoreactivity in the intermediate layers and the intense immunoreactivity in the superficial layers were not associated with de novo translated receptor protein [7] . Therefore, the receptor that is present in the metabolically active but non-proliferating granular (skin) and intermediate layers (in the ectocervix), and in cells in the more superficial layers, represents receptor trapped in dying cells that undergo terminal differentiation. These cells start to lose their cytoplasm, and as they flatten, the density of the retained P2X 7 immunoreactivity increases (e.g., Fig. 6a) . From a biological point of view, the P2X 7 receptor in those cells could function to mediate apoptosis associated with terminal differentiation. However, this is a secondary function compared to its main role, which is regulation of growth of the proliferating cells in the basal/parabasal layers (and in hair shafts in the skin). These proliferating cells are the target of carcinogenic stimuli and are at risk of undergoing the neoplastic transformation. Our previous [7] and present data that the P2X 7 receptor is expressed by proliferating epithelial cells support the hypothesis that P2X 7 plays an important role in the regulation and control of growth of epithelial cells.
Based on these data, it is proposed that epithelia can be characterized according to the pattern of P2X 7 expression in normal and cancer cells: (a) epithelia with a similar trend of expression in normal and cancer cells, e.g., the colon (present data), in which the role of P2X 7 in the genesis and development of the cancer is relatively small; (b) epithelia with high expression of the P2X 7 in cancer cells, e.g., thyrocytes-Whether in those cases the cancer cells overproduce the receptor as an inherent growth protective mechanism, or whether the P2X 7 stimulates proliferation [34] , remains to be determined; and (c) epithelia in which P2X 7 expression is decreased already in early phases of the neoplasia, e.g., the uterine epithelia, bladder, and breast. This could abrogate apoptosis and lead to unstable tissue kinetics, favoring an increase in total cell number and tumor cellular expansion in cells exposed to the carcinogenic stimulus [28] . One possibility is that the neoplastic stimulus triggers decreased expression of the P2X 7 , thereby contributing to uncontrolled cell growth. The present data in endometrial and bladder cells of low expression of the P2X 7 receptor already in pre-cancerous and early cancerous cells support this hypothesis. However, a more fundamental possibility is that the decrease in P2X 7 expression occurs prior to the neoplastic transformation, as was observed in cases of cervical dysplasia (e.g., Fig. 1c, g ), where the abrogation of P2X 7 -mediated apoptosis could be responsible for the preservation of genetically aberrant cells that are susceptible to carcinogenic stimuli, favoring neoplastic transformation [54] . In the cervix, virulent human papilloma viruses (HPV) contribute to the development of dysplasia and possibly squamous cell carcinoma [55] . However, only few cases of dysplasia progress to cancer [55] . The present data showed that decreased expression of the P2X 7 was observed already in cases of mild-moderate dysplasia, which usually do not transform into cancer. Therefore, it is possible that in the cervix the decreased expression of the P2X 7 precedes the carcinogenic stimulus, thereby increasing the risk of neoplastic transformation of HPV-infected cells.
Collectively, our past and present observations and the data of Greig et al. [28] support the hypothesis that in the uterus, bladder, breast, and skin the P2X 7 mechanism plays a physiological role in the control of epithelial cell growth. The data suggest an embryologic background to the tissuespecific expression of the P2X 7 . Accordingly, in cancer cells of epithelia derived from the endoderm (thyroid and colon), P2X 7 receptors levels are higher or equal to those in normal cells. In contrast, in cancer cells of epithelia derived from the ectoderm (skin and breast), the uro-genital sinus (bladder and ectocervix), and the distal paramesonephric (Müllerian) duct (endocervix and endometrium), P2X 7 receptors levels are low. It is therefore possible that early embryonic events imprint P2X 7 expression in the later stage of life.
The mechanism that determines low expression of P2X 7 receptor in uterine, bladder, breast, and possibly skin epithelial cancer cells is at present unknown. P2X 7 mRNA steady-state levels in these epithelia were also low in the cancer tissues (present data and unpublished data [skin]), suggesting an effect already at the mRNA level. Since the decrease of P2X 7 mRNA in cancer cells was quantitatively greater than that of the P2X 7 receptor, the effect most likely is not translational. More likely, based on a recent study [25] , the effect is post-transcriptional, involving enhanced instability of the 3′ untranslated region (3′-UTR) of the P2X 7 gene, through the action of micro-RNAs (miRNAs). In the human cervix and endometrium, miRNAs miR-150 and miR-186 were identified as two factors that regulate P2X 7 3′-UTR, and cellular levels of these miRNAs were higher in the cancer than normal epithelial cells. However, little is known about the role of miRNAs in the regulation P2X 7 3′-UTR in the bladder, breast, and skin epithelia.
In summary, we found decreased expression of the functional full-length P2X 7 receptor in cancer cells of epithelia derived from the ectoderm, the uro-genital sinus, and the distal paramesonephric duct. In the ectocervix endometrium and bladder, P2X 7 receptor levels were lower also in dysplastic, pre-cancerous, and early cancerous epithelial cells. Since P2X 7 -mediated apoptosis is an important mechanism that regulates epithelial cell growth, it is possible that early embryonic events imprint P2X 7 expression in the later stage of life and confer the risk of cancer development in those tissues.
